BLUE News and Press, bluebird bio Inc. From 05/09/22

Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million...

A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...

The past few years have been harsh on Bluebird Bio (NASDAQ: BLUE) . The rare-diseases-focused, gene-therapy specialist ran into a series of clinical and regulatory headwinds, which played a major role in its catastrophic performance in the stock market since 2019. Bluebird's shares ...

The "What's Working" list is dominated by sectors that have already done well in 2022 (energy, metals, defense, staples). "What's Not Working" was populated with "risk on" ETFs like ARKK, biotech, and semiconductors. We give you more commentary on rates and inflation and accelerat...

With its shares down by around 84% in the past year, it's a wonder that investors are still interested in Bluebird Bio (NASDAQ: BLUE) at all. It withdrew its beta thalassemia drug, Zynteglo, from the E.U. market over persistent pricing conflicts with regulators there in August 2021....

Bluebird Bio (BLUE -3.8%) slides after brokerage Cowen downgrades to Market Perform from Outperform following the company's restructuring announcement. Cowen analyst Yaron Werber has concerns about the company's commercial outlook, especially given its lag to market and the competitive s...

Bluebird bio (NASDAQ:BLUE) announced plans to reduce its staff by nearly 30% on Tuesday as the troubled gene therapy biotech targets up to $160 million in cost savings over the next two years in a bid to extend the cash runway into 1H 2023. The restructuring initiative includes plans to depri...

Expected to deliver up to $160 million in cost savings over the next two years and extend the Company’s cash runway through pivotal upcoming milestones in the first half of 2023 Management team to host conference call today, April 5, 2022 at 8:00 am ET Followi...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...